The cytotoxic effects of preserved and preservative-free prostaglandin analogs on human corneal and conjunctival epithelium in vitro and the distribution of benzalkonium chloride homologs in ocular surface tissues in vivo

Current Eye Research

Volumn 37, Issue 2, 2012, Pages 145-154

  Pellinen, Pertti ^a   Huhtala, Anne ^b   Tolonen, Ari ^c   Lokkila, Jukka ^a   Mäenpää, Jukka ^a   Uusitalo, Hannu ^b  

^a Santen Oy   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c Novamass Ltd   (Finland)

Author keywords

Benzalkonium chloride; Conjunctival epithelial cells; Corneal epithelial cells; Cytotoxicity; Prostaglandin analog; Rabbit eye

Indexed keywords

BENZALKONIUM CHLORIDE; BIMATOPROST; CETALALKONIUM CHLORIDE; LACTATE DEHYDROGENASE; LATANOPROST; LAURALKONIUM CHLORIDE; MIRISTALKONIUM CHLORIDE; PRESERVATIVE; PROSTAGLANDIN DERIVATIVE; REAGENT; TAFLUPROST; TRAVOPROST; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CELL VIABILITY; CONCENTRATION RESPONSE; CONJUNCTIVA EPITHELIUM; CONTROLLED STUDY; CORNEA EPITHELIUM; DRUG CYTOTOXICITY; DRUG EFFECT; ENZYME ASSAY; IN VITRO STUDY; IN VIVO STUDY; MEMBRANE STABILIZATION; NONHUMAN; PRIORITY JOURNAL; RABBIT; STATISTICAL SIGNIFICANCE; SURFACE PROPERTY;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZALKONIUM COMPOUNDS; CELL LINE; CELL SURVIVAL; CONJUNCTIVA; EPITHELIUM; EPITHELIUM, CORNEAL; HUMANS; L-LACTATE DEHYDROGENASE; MALE; OPHTHALMIC SOLUTIONS; PRESERVATIVES, PHARMACEUTICAL; PROSTAGLANDINS F, SYNTHETIC; RABBITS; TISSUE DISTRIBUTION;

EID: 84856120314     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2011.626909     Document Type: Article

References (47)

1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262-267. (Pubitemid 43325451)
2. Perry CM, McGavin JK, Culy CR, Ibbotson T. Latanoprost: An update of its use in glaucoma and ocular hypertension. Drugs Aging. 2003;20:597-630. (Pubitemid 36808230)
3. Waugh J, Jarvis B. Travoprost. Drugs Aging. 2002;19:465-71; discussion 472.
4. Cantor LB. Clinical pharmacology of bimatoprost. Expert Opin Drug Metab Toxicol. 2005;1:151-157.
5. Bean GW, Camras CB. Commercially available prostaglandin analogs for the reduction of intraocular pressure: Similarities and differences. Surv Ophthalmol. 2008;53:69-84.
6. Takagi Y, Nakajima T, Shimazaki A et al. Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. Exp Eye Res. 2004;78:767-776. (Pubitemid 38252953)
7. Sutton A, Gilvarry A, Ropo A. A comparative, placebo-controlled study of prostanoid fluoroprostaglandin-receptor agonists tafluprost and latanoprost in healthy males. J Ocul Pharmacol Ther. 2007;23:359-365. (Pubitemid 350195060)
8. Sutton A, Gouws P, Ropo A. Tafluprost, a new potent prostanoid receptor agonist: A dose-response study on pharmacodynamics and tolerability in healthy volunteers. Int J Clin Pharmacol Ther. 2008;46:400-406.
9. Uusitalo H, Pillunat LE, Ropo A. Phase III study investigators. Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study. Acta Ophthalmol. 2010;88:12-19.
10. Traverso CE, Ropo A, Papadia M, Uusitalo H. A phase II study on the duration and stability of the intraocular pressure- lowering effect and tolerability of tafluprost compared with latanoprost. J Ocul Pharmacol Ther. 2010;26:97-104.
11. Furrer P, Mayer JM, Plazonnet B, Gurny R. Ocular tolerance of absorption enhancers in ophthalmic preparations. AAPS PharmSci. 2002;4:2.
12. Noecker R. Effects of common ophthalmic preservatives on ocular health. Adv Ther. 2001;18:205-215. (Pubitemid 33131188)
13. Herreras JM, Pastor JC, Calonge M, Asensio VM. Ocular surface alteration after long-term treatment with an antiglaucomatous drug. Ophthalmology. 1992;99:1082-1088.
14. Burstein NL. Preservative cytotoxic threshold for benzalkonium chloride and chlorhexidine digluconate in cat and rabbit corneas. Invest Ophthalmol Vis Sci. 1980;19:308-313. (Pubitemid 11067930)
15. Baudouin C. Detrimental effect of preservatives in eyedrops: Implications for the treatment of glaucoma. Acta Ophthalmol. 2008;86:716-726.
16. Epstein SP, Ahdoot M, Marcus E, Asbell PA. Comparative toxicity of preservatives on immortalized corneal and conjunctival epithelial cells. J Ocul Pharmacol Ther. 2009;25:113-119.
17. Euerby MR. High performance liquid chromatography of benzalkonium chlorides-variation in commercial preparations. J Clin Hosp Pharm. 1985;10:73-77. (Pubitemid 15103373)
18. Smith MJ, Flowers TH, Cowling MJ, Duncan HJ. Method for the measurement of the diffusion coefficient of benzalkonium chloride. Water Res. 2002;36:1423-1428. (Pubitemid 34230337)
19. Herman JR, Bass P. Enteric neuronal ablation: Structureactivity relationship in a series of alkyldimethylbenzylammonium chlorides. Fundam Appl Toxicol. 1989;13:576-584. (Pubitemid 19271778)
20. Prince SJ, McLaury HJ, Allen LV, McLaury P. Analysis of benzalkonium chloride and its homologs: HPLC versus HPCE. J Pharm Biomed Anal. 1999;19:877-882. (Pubitemid 29127201)
21. Adriaens E, Dierckens K, Bauters TG et al. The mucosal toxicity of different benzalkonium chloride analogues evaluated with an alternative test using slugs. Pharm Res. 2001;18:937-942. (Pubitemid 32799937)
22. Erhart M, Zilliox P, De Burlet GL, Andermann G. Differences in ocular toxicity and antimicrobial activity of benzalkonium chlorides. Concepts Toxicol. 1987;4:145-151.
23. Daoud NN, Dickinson NA, Gilbert P. Antimicrobial activity and physico-chemical properties of some alkyldimethylbenzylammonium chlorides. Microbios. 1983;37:73-85. (Pubitemid 13016328)
24. Araki-Sasaki K, Ohashi Y, Sasabe T et al. An SV40- immortalized human corneal epithelial cell line and its characterization. Invest Ophthalmol Vis Sci. 1995;36:614-621.
25. Diebold Y, Calonge M, Enriquez de Salamanca A et al. Characterization of a spontaneously immortalized cell line (IOBA-NHC) from normal human conjunctiva. Invest Ophthalmol Vis Sci. 2003;44:4263-4274. (Pubitemid 37186260)
26. Green K, Chapman J, Cheeks L, et al. Detergent penetration into young and adult rabbit eyes: Comparative pharmacokinetics. J Toxicol-Cut & Ocular Toxicol. 1987;6:89-107. (Pubitemid 17166396)
27. Hollo G. The side effects of the prostaglandin analogues. Expert Opin Drug Saf. 2007;6:45-52. (Pubitemid 46150523)
28. Hylton C, Robin AL. Update on prostaglandin analogs. Curr Opin Ophthalmol. 2003;14:65-69. (Pubitemid 36584222)
29. Kahook MY, Noecker RJ. Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears. Cornea. 2008;27:339-343. (Pubitemid 351440870)
30. Whitson JT, Cavanagh HD, Lakshman N, Petroll WM. Assessment of corneal epithelial integrity after acute exposure to ocular hypotensive agents preserved with and without benzalkonium chloride. Adv Ther. 2006;23:663-671. (Pubitemid 44955845)
31. McCarey B, Edelhauser H. In vivo corneal epithelial permeability following treatment with prostaglandin analogs [correction of analoges] with or without benzalkonium chloride. J Ocul Pharmacol Ther. 2007;23:445-451. (Pubitemid 350202478)
32. Spielmann H. White Paper of the European Commission- strategy for a new chemicals policy. Altex. 2002;19:20-25.
33. Yee RW, Norcom EG, Zhao XC. Comparison of the relative toxicity of travoprost 0.004% without benzalkonium chloride and latanoprost 0.005% in an immortalized human cornea epithelial cell culture system. Adv Ther. 2006;23:511-519.
34. Baudouin C, Riancho L, Warnet JM, Brignole F. In vitro studies of antiglaucomatous prostaglandin analogues: Travoprost with and without benzalkonium chloride and preserved latanoprost. Invest Ophthalmol Vis Sci. 2007;48:4123-4128. (Pubitemid 351261038)
35. Guenoun JM, Baudouin C, Rat P, Pauly A, Warnet JM, Brignole-Baudouin F. In vitro comparison of cytoprotective and antioxidative effects of latanoprost, travoprost, and bimatoprost on conjunctiva-derived epithelial cells. Invest Ophthalmol Vis Sci. 2005;46:4594-4599. (Pubitemid 44264559)
36. Guenoun JM, Baudouin C, Rat P, Pauly A, Warnet JM, Brignole-Baudouin F. In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells. Invest Ophthalmol Vis Sci. 2005;46:2444-2450. (Pubitemid 43119492)
37. Goto Y, Ibaraki N, Miyake K. Human lens epithelial cell damage and stimulation of their secretion of chemical mediators by benzalkonium chloride rather than latanoprost and timolol. Arch Ophthalmol. 2003;121:835-839. (Pubitemid 36676221)
38. Hamard P, Blondin C, Debbasch C, Warnet JM, Baudouin C, Brignole F. In vitro effects of preserved and unpreserved antiglaucoma drugs on apoptotic marker expression by human trabecular cells. Graefes Arch Clin Exp Ophthalmol. 2003;241:1037-1043. (Pubitemid 38028900)
39. Brasnu E, Brignole-Baudouin F, Riancho L, Guenoun JM, Warnet JM, Baudouin C. In vitro effects of preservative- free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line. Curr Eye Res. 2008;33:303-312. (Pubitemid 351507760)
40. Uematsu M, Kumagami T, Shimoda K et al. Influence of alkyl chain length of benzalkonium chloride on acute corneal epithelial toxicity. Cornea. 2010;29:1296-1301.
41. Liang H, Baudouin C, Pauly A, Brignole-Baudouin F. Conjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride. Br J Ophthalmol. 2008;92:1275-1282.
42. Baudouin C. The ocular surface in glaucoma. Cornea. 2009;28:14-18.
43. Hommer A. A review of preserved and preservative-free prostaglandin analogues for the treatment of open-angle glaucoma and ocular hypertension. Drugs Today. 2010;46:409-416.
44. Hamacher T, Airaksinen J, Saarela V, Liinamaa MJ, Richter U, Ropo A. Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: Results from a pharmacodynamics analysis. Acta Ophthalmol Suppl (Oxf). 2008;242:14-19.
45. Pellinen P, Lokkila J. Corneal penetration into rabbit aqueous humor is comparable between preserved and preservativefree tafluprost. Ophthalmic Res. 2009;41:118-122.
46. Uusitalo H, Chen E, Pfeiffer N et al. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmol. 2010;88:329-336.
47. Champeau EJ, Edelhauser HF. Effect of ophthalmic preservatives on the ocular surface. conjunctival and corneal uptake of benzalkoium chloride and chlorhexidine digluconate. In: Holly FJ, editor. The preocular tear film in health, disease and contact lens wearers. Dry Eye Inst (November 1986), Lubbock, TX 1986 p. 292-302.